Cleary Gottlieb Steen & Hamilton and Slaughter and May have teamed up to advise GlaxoSmithKline (GSK) on its $210m (£128m) acquisition of some of Bristol Myers Squibb's (BMS's) Egyptian assets.

The pair worked opposite DLA Piper on the deal, which sees GSK buying BMS's Egyptian mature products business.

Cleary Gottlieb fielded a team under London-based US capital markets partner Sebastian Sperber, with assistance from partner Sheldon Alster on the tax side as well as a team of associates. The New York law firm advised GSK on all of the US aspects of the deal, which was agreed under New York law.

Slaughter and May, meanwhile, advised the pharmaceutical giant on the UK components of the transaction, with M&A partner David Johnson taking the lead role for GSK assisted by associates Chris McGaffin and Miles McCarthy.

Slaughters counts GSK as a longstanding client, with the magic circle law firm emerging as the organisation's main UK corporate adviser in 2001. The firm had previously advised GlaxoWellcome on its 2000 merger with SmithKline Beecham when Linklaters acted for SmithKline.

BMS, meanwhile, turned to DLA Piper, which fielded a team from its New York office and its Cairo alliance firm DLA Matouk Bassiouny. New York corporate partner David Weiss took the lead role in the US while office managing partner John Matouk and executive partner Omar Bassiouny advised from Cairo.

More news, deals and comment on Cleary Gottlieb Steen & Hamilton

Cleary Gottlieb Steen & Hamilton on the Legal Week Wiki

More news, deals and comment on Slaughter and May

Slaughter and May on the Legal Week Wiki